WP
CADL icon

Woodline Partners’s Candel Therapeutics CADL Stock Holding History

Woodline Partners’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$768K Buy
+156,700
New +$853K ﹤0.01% 912
2022
Q1 		– Sell
-100,000
Closed -$782K – 736
2021
Q4 		$782K Hold
100,000
– – 0.01% 525
2021
Q3 		$1.08M Buy
+100,000
New +$829K 0.02% 502

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners's CADL Position: Q1 2026 in Review

Woodline Partners opened a new position in Candel Therapeutics (CADL) in Q1 2026: 156,700 shares worth $768K. The stake represents ﹤0.01% of the portfolio and ranks #912 among its holdings. This is a return to the name: Woodline Partners previously reported a position in CADL as recently as Q4 2021.

Woodline Partners first reported a position in CADL in Q3 2021 and has held it in 3 quarters since. The position peaked at $1.08M in Q3 2021. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Woodline Partners held 156,700 shares of Candel Therapeutics worth $768K as of Q1 2026.
  • Candel Therapeutics was a new Woodline Partners position in Q1 2026.
  • Candel Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q1 2026, its #912 holding.
  • Woodline Partners first reported a position in Candel Therapeutics in Q3 2021 and has held it in 3 quarters since.
  • Woodline Partners's Candel Therapeutics position peaked at $1.08M in Q3 2021.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.